Cagrilintide
Long-acting amylin analog being developed for obesity and type 2 diabetes (as CagriSema with semaglutide). Half-life of 159-195 hours (~7 days) supports once-weekly dosing. Amylin receptor activation reduces appetite, slows gastric emptying, and decreases glucagon secretion. Phase 3 trials ongoing in combination with semaglutide 2.4 mg.
Projected serum levels — 2.4 mg, weekly
Maintenance schedule: 2.4 mg weekly (subcutaneous).
Loading schedule: 5.2 mg on day 1, then 2.4 mg weekly — reaching therapeutic levels sooner.
Modeled steady state after ~21 days: peak ≈ 4.3 mg, trough ≈ 2.7 mg body load. Population-based estimate over 63 days for a 2.4 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Peptide
- Route modeled
- Subcutaneous
- Model confidence
- inferred
- Half-life
- 7.5 days
- Common dose
- 2.4 mg
- Suggested maximum
- 4.5 mg/day
- Reference dose range
- 1.2–4.5 mg (single dose)
- Suggested cadence
- weekly
Research behind this entry
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management
Phase 1b trial establishing cagrilintide PK (half-life 159-195 h, Tmax 24-72 h) and demonstrating dose-dependent weight loss up to 17.1% when combined with semaglutide 2.4 mg over 20 weeks.
-
Development of Cagrilintide, a Long-Acting Amylin Analogue
Described the medicinal chemistry optimization of cagrilintide, a fatty acid-acylated amylin analog with dramatically extended half-life enabling weekly dosing via albumin binding.
2 published studies referenced in the app, each with a plain-language summary.